Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties... Show more
a provider of drug development services
Industry Biotechnology
A.I.dvisor indicates that over the last year, RPRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RPRX jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To RPRX | 1D Price Change % | ||
|---|---|---|---|---|
| RPRX | 100% | -1.11% | ||
| AXON - RPRX | 48% Loosely correlated | +2.64% | ||
| INCY - RPRX | 40% Loosely correlated | -0.21% | ||
| HALO - RPRX | 36% Loosely correlated | -1.10% | ||
| VRTX - RPRX | 34% Loosely correlated | -1.77% | ||
| RIGL - RPRX | 34% Loosely correlated | -2.58% | ||
More | ||||
RPRX saw its Momentum Indicator move below the 0 level on August 13, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned negative. In of the 88 cases, the stock moved further down in the following days. The odds of a decline are at .
The Moving Average Convergence Divergence Histogram (MACD) for RPRX turned negative on July 31, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RPRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 58 cases where RPRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RPRX advanced for three days, in of 311 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 260 cases where RPRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.820) is normal, around the industry mean (20.281). P/E Ratio (31.511) is within average values for comparable stocks, (25.508). Projected Growth (PEG Ratio) (2.075) is also within normal values, averaging (3.845). Dividend Yield (0.016) settles around the average of (0.019) among similar stocks. P/S Ratio (12.903) is also within normal values, averaging (437.072).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.